Highly phosphorylated and sulfated recombinant factor IX

Details Highly phosphorylated and sulfated recombinant factor IX Highly phosphorylated and sulfated recombinant factor IX

2008-03-28

2009-08-18

Monshipouri, Maryam (Department: 1656)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

Reexamination Certificate

active

07575897

ABSTRACT:
The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

REFERENCES:
patent: 0 669 342 (1995-02-01), None
patent: WO 94/20078 (1994-09-01), None
patent: WO 94/23701 (1994-10-01), None
patent: WO 96/06638 (1996-03-01), None
Altschul, Stephen, et al., “Basic Local Alignment Search Tool,” J. Mol. Biol., 1990, vol. 215, pp. 403-410.
Altschul, Stephen, et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, 1997, vol. 25, No. 17, pp. 3389-3402.
Arruda, Valder, et al., “Posttranslational modifications of recombinant myotube-synthesized human factor IX,” Blood, 2001, vol. 97, No. 1, pp. 130-138.
Autin, et al., “Molecular models of the procoagulant factor Vllla-factor IXa complex,” Journal of Thrombosis and Haemostasis, 2005, vol. 3, No. 9, pp. 2044-2056.
Björkman, S., et al., “Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis,” Haemophilia, 2001, vol. 7, pp. 133-139.
Bond, M. et al., “Biochemical Characterization of Recombinant Factor IX,” Seminars in Hematology, 1998, vol. 35, No. 2, Suppl 2., pp. 11-17.
Brinkhous, Kenneth, et al., “Recombinant Human Factor IX: Replacement Therapy, Prophylaxis, and Pharmacokinetics in Canine Hemophilia B,” 1996, vol. 88, No. 7, pp. 2603-2610.
Chen, CC, et al., “The aPTT assay as a monitor of heparin anticoagulation efficacy in clinical settings,” Adv. Ther., 2003, vol. 20, No. 5, pp. 231-236.
Choo, K.H. “Molecular cloning of the gene for human anti-haemophilic factor IX,” Nature, 1982, vol. 299, pp. 178-180.
Coombes AG, et al., “Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen,” Vaccine, 1996, vol. 14, No. 15 pp. 1429-1438.
Ewenstein, B.M., et al., “Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B,” Transfusion, 2002, vol. 42, No. 2, pp. 190-197.
Harrison, S, et al., “The Manufacturing Process for Recombinant Factor IX,” Seminars in Hematology, 1998, vol. 35, No. 2, Suppl 2, pp. 4-10.
Henikoff, Steven, et al., “Amino Acid Substitution Matrices from Protein Blocks,” Proc. Natl. Acad. Sci. USA, 1992, vol. 89, pp. 10915-10919.
Herlitschka, Sabine, et al., “Overexpression of Human Prothrombin in Permanent Cell Lines Using a Dominant Selection/Amplification Fusion Marker,” Protein Expression and Purification, 1996, vol. 8, pp. 358-364.
Jaye, Michael, et al., “Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX,” 1983, Nucleic Acids Research, vol. 11, No. 8, pp. 2325-2335.
Kaufman, Randal, et al., “Expression, Purification, and Characterization of Recombinant γ-Carboxylated Factor IX Synthesized in Chinese Hamster Ovary Cells,” The Journal of Biological Chemistry, 1986, vol. 261, No. 21, pp. 9622-9628.
Kaufman, Randal. et al., “Post-translational Modification Required for Coagulation Factor Secretion and Function,” Thromb Haemost, 1998, vol. 79, pp. 1068-1079.
Keith, James., et al., “Evaluation of Recombinant Human Factor IX: Pharmacokinetic Studies in the Rat and the Dog,” Trombosis and Haemostasis, 1995, vol. 73, pp. 101-105.
Kisker, C.T., et al., “Prophylaxis in factor IX deficiency product and patient variation,” Haemophilia, 2003, vol. 9, pp. 279-284.
Kurachi, Kotoku, et al., “Isolation and characterization of a cDNA coding for human factor IX,” Proc. Natl. Acad. Sci. USA, 1982, vol. 79, pp. 6461-6464.
Mammalian Gene Collection (MGC) Program Team, “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,” PNAS, 2002, vol. 99, No. 26, pp. 16899-16903.
McCarthy, K., et al., “Pharmacokinetics of Recombinant Factor IX after Intravenous and Subcutaneous Administration in Dogs and Cynomolgus Monkeys,” 2002, Thromb Haemost, vol. 87, pp. 824-830.
McGraw, R.A., et al., “Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX,” Proc. Natl. Acad. Sci. USA, 1985, vol. 82, pp. 2847-2851.
Needleman, Saul, et al. “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol. 1970, vol. 48, pp. 443-453.
Pearson, William, et al., “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci. USA, 1988, vol. 85, pp. 2444-2448.
Poon, Man-Chiu, “Recombinant Factor IX Recovery and Inhibitor Safety: a Canadian Post-licensure Surveillance Study,” Thrombosis and Haemostasis, 2002, vol. 87, pp. 431-435.
Ragni, M.V., et al., “Use of recombinant factor IX in subjects with haemophilia B undergoing surgery,” 2002, vol. 8, pp. 91-97.
Rost, Simone, et al., “Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2,” Nature, 2004, vol. 427, pp. 537-544.
Roth, David, et al., “Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates,” Blood, 2001, vol. 98, No. 13, pp. 3600-3606.
Scahill, Shaun, et al., “Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster overy cells,” Proc. Natl. Acad. Sci USA, 1983, vol. 80, pp. 4654-4658.
Schaub, R. et al. , “Preclinical Studies of Recombinant Factor IX,” Seminars in Hematology, 1998, vol. 35, No. 2, Suppl. 2, pp. 28-32.
Shapiro, A.D., et al., “Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia,” Haemophilia, 2005, vol. 11, pp. 571-582.
Shapiro, Amy, et al., “The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B,” Blood, 2005, vol. 105. No. 2, pp. 518-525.
Smith, Temple, et al., “Comparison of Biosequences,” Advances in Applied Mathematics, 1981, vol. 2., pp. 482-489.
Wasley, Louise, et al. “PACE/Furin Can Process the Vitamin K-dependent Pro-factor IX Precursor within the Secretory Pathway,” The Journal of Biological Chemistry, 1993, vol. 268, No. 12, pp. 8458-8465.
White, Gilbert, “Recombinant Factor IX,” Thrombosis and Haemostasis, 1997, vol. 78., No. 1., pp. 261-265.
White, Gilbert., “Mammalian Recombinant Coagulation Proteins: Structure and Function,” Transfus. Sci., 1998, vol. 19, No. 2, pp. 177-189.

Affiliated with

Also associated with

Rating

Highly phosphorylated and sulfated recombinant factor IX does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Highly phosphorylated and sulfated recombinant factor IX, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Highly phosphorylated and sulfated recombinant factor IX will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4126390